TXN10128 / Txinno Biosci - LARVOL DELTA

A Study of TXN10128 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=96 | Recruiting | Sponsor: Txinno Bioscience Inc. | N=36 ➔ 96 | Trial completion date: Aug 2025 ➔ Jun 2026 | Trial primary completion date: Mar 2025 ➔ Dec 2025

Enrollment change • Monotherapy • Trial completion date • Trial primary completion date • Solid Tumor

Preclinical and IND-enabling studies of TXN10128, an ENPP1 inhibitor, for clinical evaluation in patients with solid tumor (SITC 2023) - "Conclusions Together with significant in vivo efficacies in various combination settings and supportive toxicology profile, these studies demonstrated that TXN10128 is a suitable candidate for clinical investigation as a combination partner with existing therapies. Ph I dose escalation study of TXN10128 monotherapy is currently enrolling solid tumor patients in Korea and dose-escalation study of combination therapy will be commencing in near future."

IO biomarker • Preclinical • Oncology • Solid Tumor • CXCL10 • STING • TNFA

A Study of TXN10128 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Recruiting | Sponsor: Txinno Bioscience Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

A Study of TXN10128 in Subjects With Solid Tumors (clinicaltrials.gov) - P1 | N=36 | Not yet recruiting | Sponsor: Txinno Bioscience Inc.

Metastases • New P1 trial • Oncology • Solid Tumor